评估体位性心动过速综合征中急性肝卟啉症的患病率
估计体位性心动过速综合征中急性肝卟啉症的频率和神经激素特征
Postural Tachycardia Syndrome (POTS) is the most common autonomic disorder and is estimated to affect 3,000,000 individuals in the United States, with 80-85% of patients being women. The condition is characterized by a rapid increase in heart rate (HR) that occurs on standing, and chronic symptoms of cerebral hypoperfusion leading to lightheadedness, dizziness, and blurred vision.
The acute hepatic porphyrias(AHP)are among the diseases that present with autonomic cardiovascular(tachycardia)and neurovisceral symptoms (abdominal pain) among others; they present with acute exacerbations Given that there is available treatment for AHP that change the natural progression of the disease, study focuses to investigate the occurrence of AHP in POTS and determine the clinical and neuro-hormonal characteristic of the POTS subgroup that will likely benefit from AHP screening.
This study has one visit that involves, answering some questionnaires, coming to the lab for blood work, genetic testing, and some autonomic function tests. About 50 people will take part in this study.
研究概览
地位
详细说明
Postural Tachycardia Syndrome (POTS) affects ~3 million young women in the United States.(1)These patients have a low quality of life because of chronic presyncopal symptoms, and orthostatic tachycardia that occur while standing. POTS can be the initial presentation of an underlying illness. A substantial group of patients with POTS reported that their symptoms started after an acute illness, surgical intervention, substantial weight loss or after ingesting certain medications. These are the same triggers for acute AHP attacks.
Furthermore, the demographic characteristics of AHP overlaps with that of POTS. AHP also affects primarily young women, in their reproductive age. POTS can have a diverse presentation, some patients present with axonal autonomic neuropathy, and severe gastrointestinal symptoms which are co-morbid conditions also present in chronic AHP.
It is within this context that investigators propose to assess the occurrence of AHP in the general POTS population, identify its clinical presentation and neuro-hormonal characteristics.
Rationale and Endpoints:
- To evaluate occurrence of AHPs in POTS patients with autonomic and neurovisceral symptoms referred to a National Referral Center for the treatment of Autonomic Disorder.
- To determine the autonomic and neuro-hormonal characteristics of AHP-POTS patients compared with POTS patients
Enrollment:
This is a cross-sectional study conducted at the Vanderbilt Autonomic Dysfunction Clinic (ADC). Investigators plan to enroll patients with suspicions of POTS who are referred to the ADC for evaluation and diagnosis.
Study visit:
Single study visit.
Participants will be asked to complete an autonomic symptoms assessment questionnaire (COMPASS 31), and quality of life EQ-5D.
The following laboratory analyses will be performed:
Blood: CBC, CMP, Iron studies (Ferritin and iron studies) Urine PBG, ALA and porphyrins in a spot urine sample with results normalized to urine creatinine.
Genetic testing (Acute hepatic porphyria panel) .
Autonomic function test.
Supine and Standing plasma norepinephrine will be obtained for evaluation of neuro-hormonal changes during orthostasis.
Statistical Analyses
This is a pilot study that will estimate the occurrence of AHPs in POTS patients referred to a National Referral Center for the Treatment of Autonomic Disorders. There is no data available on the prevalence of AHPs in POTS. The prevalence of AHP is one in 6,000 in whites. [ref. Hepatol commun 2019 feb 3(2): 193-206] Given that there are overlapping of symptoms between AHP and POTS, expected that AHP would be overrepresented in POTS patients. The plan is to enroll 50 POTS patients in this pilot study.
Data Analysis Plan:
Standard graphing and screening techniques will be used, to detect outliers and to ensure data accuracy. Continuous endpoints will be assessed for normality. If normality is violated, data transformation will be applied or non-parametric analysis methods will be considered. Investigators will provide summary statistics for both continuous and categorical variables by subject groups (POTS and AHP-POTS). All hypotheses will be tested, at the level of α=0.05. SPSS (version 23.0, SPSS, Chicago, IL) will be used and the open-source statistical package R (R Core Team, 2019 for analyses.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Tennessee
-
Nashville、Tennessee、美国、37232
- Vanderbilt University Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Postural Tachycardia Syndrome
描述
Inclusion Criteria
- Age 18 - 65 years
- Individuals having an established diagnosis of POTS defined as the presence of presyncopal symptoms for more than 6 months and orthostatic tachycardia (>30 bpm increase in HR within 10 min after assuming upright position)
- The present of one of the following criteria:
3.1 Family history of acute hepatic porphyria 3.2 Unexplained recurrent (more than one), prolonged (>24 hours) episode of severe, diffuse (poorly localized) abdominal pain AND at least TWO of the following:
- Red to brownish urine.
- Blistering skin lesions on sun-exposed areas.
- Peripheral nervous system manifestations occurring around the time of abdominal pain (i.e., motor neuropathy (paresis), sensory neuropathy (numbness, tingling, limb pain).
- Central nervous system manifestations occurring around the time of abdominal pain (i.e. confusion, anxiety, seizures, hallucinations).
- Autonomic nervous system manifestations occurring around the time of abdominal pain (i.e. hyponatremia(Na<lower limit of normal)), tachycardia, hypertension, nausea and vomiting, constipation).
Exclusion Criteria
- Pregnant or breastfeeding women
- type 2 diabetes mellitus
- History of alcohol or drug abuse
- Inability to provide informed consent or comply with protocol
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_ONLY
- 时间观点:CROSS_SECTIONAL
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
AHP Case ascertainment in POTS patients
大体时间:During the intervention
|
Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome |
During the intervention
|
合作者和调查者
调查人员
- 首席研究员:Cyndya Shibao, M.D、Vanderbilt University Medical Center
出版物和有用的链接
一般刊物
- Garland EM, Raj SR, Black BK, Harris PA, Robertson D. The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome. Neurology. 2007 Aug 21;69(8):790-8. doi: 10.1212/01.wnl.0000267663.05398.40.
- Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology. 1993 Jan;43(1):132-7. doi: 10.1212/wnl.43.1_part_1.132.
- Raj SR. The Postural Tachycardia Syndrome (POTS): pathophysiology, diagnosis & management. Indian Pacing Electrophysiol J. 2006 Apr 1;6(2):84-99.
- Loavenbruck A, Iturrino J, Singer W, Sletten DM, Low PA, Zinsmeister AR, Bharucha AE. Disturbances of gastrointestinal transit and autonomic functions in postural orthostatic tachycardia syndrome. Neurogastroenterol Motil. 2015 Jan;27(1):92-8. doi: 10.1111/nmo.12480. Epub 2014 Dec 6.
- Robertson D; New Collective Author. The epidemic of orthostatic tachycardia and orthostatic intolerance. Am J Med Sci. 1999 Feb;317(2):75-7. doi: 10.1097/00000441-199902000-00001. No abstract available.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 210724
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.